Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020.
Breast cancer
Canada
Costing
Outcomes
Real-world evidence
Survival
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
24
08
2023
accepted:
05
11
2023
pubmed:
21
12
2023
medline:
21
12
2023
entrez:
21
12
2023
Statut:
ppublish
Résumé
To enable the integration of novel therapies, it is critical to understand current long-term outcomes in HER2-positive metastatic breast cancer (mBC), including survival, treatment patterns, and costs. We sought to define these outcomes among patients with mBC in Ontario. We conducted a retrospective population-level study in Ontario women diagnosed with breast cancer of any stage between January 1, 2005 and December 31, 2019, with follow-up until December 31, 2020. HER2-positivity was based on receipt of a HER2-targeted therapy (HER2-TT) in the first line (1L) metastatic setting. Administrative databases at ICES were used to assess outcomes. In Ontario, 2557 patients were diagnosed with mBC and received a HER2-TT, and of these 1606 were diagnosed with early-stage (stage I-III) that became metastatic (recurrent), while 951 were diagnosed with late stage/de novo mBC (stage IV). The average age of all patients was 54.8 years ± 12.7 years. Treatment regimens that included pertuzumab and trastuzumab (cohort name: pert_tras) were the most frequently used HER2-TT for 1L mBC (51.4%), while T-DM1 was the most frequent therapy (87.5%) in second line (2L). The median overall survival (mOS) from initiation of 1L pert_tras was not reached, whereas mOS from initiation of T-DM1 in 2L was 18.7 months. The overall mean cost per patient on pert_tras during 1L was $267,282. The main cost drivers were the cost of systemic therapy, followed by cancer clinic visits, with a mean cost per patient at $158,961 and $73,882, respectively. The baseline characteristics and treatment patterns for patients who received HER2-TT in our study align with previously reported results. However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L.
Sections du résumé
BACKGROUND
BACKGROUND
To enable the integration of novel therapies, it is critical to understand current long-term outcomes in HER2-positive metastatic breast cancer (mBC), including survival, treatment patterns, and costs. We sought to define these outcomes among patients with mBC in Ontario.
METHODS
METHODS
We conducted a retrospective population-level study in Ontario women diagnosed with breast cancer of any stage between January 1, 2005 and December 31, 2019, with follow-up until December 31, 2020. HER2-positivity was based on receipt of a HER2-targeted therapy (HER2-TT) in the first line (1L) metastatic setting. Administrative databases at ICES were used to assess outcomes.
RESULTS
RESULTS
In Ontario, 2557 patients were diagnosed with mBC and received a HER2-TT, and of these 1606 were diagnosed with early-stage (stage I-III) that became metastatic (recurrent), while 951 were diagnosed with late stage/de novo mBC (stage IV). The average age of all patients was 54.8 years ± 12.7 years. Treatment regimens that included pertuzumab and trastuzumab (cohort name: pert_tras) were the most frequently used HER2-TT for 1L mBC (51.4%), while T-DM1 was the most frequent therapy (87.5%) in second line (2L). The median overall survival (mOS) from initiation of 1L pert_tras was not reached, whereas mOS from initiation of T-DM1 in 2L was 18.7 months. The overall mean cost per patient on pert_tras during 1L was $267,282. The main cost drivers were the cost of systemic therapy, followed by cancer clinic visits, with a mean cost per patient at $158,961 and $73,882, respectively.
CONCLUSION
CONCLUSIONS
The baseline characteristics and treatment patterns for patients who received HER2-TT in our study align with previously reported results. However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L.
Identifiants
pubmed: 38127177
doi: 10.1007/s10549-023-07185-7
pii: 10.1007/s10549-023-07185-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-357Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Seung SJ, Traore AN, Pourmirza B et al (2020) A population-based analysis of breast cancer incidence and survival by subtype in Ontario women. Curr Oncol 27(2):e191–e198
doi: 10.3747/co.27.5769
pubmed: 32489268
pmcid: 7253754
Guiu S, Michiels S, André F et al (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23(12):2997–3006
doi: 10.1093/annonc/mds586
pubmed: 23166150
Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223
doi: 10.1093/annonc/mdt303
pubmed: 23917950
pmcid: 3755334
Rivenbark AG, O’Connor SM, Coleman WB (2013) Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Path 183(4):1113–1124
doi: 10.1016/j.ajpath.2013.08.002
pubmed: 23993780
pmcid: 5691324
Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747
doi: 10.1093/annonc/mdr304
pubmed: 21709140
pmcid: 3144634
Harbeck N (2018) Advances in targeting HER2-positive breast cancer. Curr Opin Obstet Gynecol 30:55–59
doi: 10.1097/GCO.0000000000000431
pubmed: 29194077
Waks AG, Winer EP (2019) breast cancer treatment: a review. JAMA 321(3):288–300
doi: 10.1001/jama.2018.19323
pubmed: 30667505
Canadian Cancer Society. Targeted therapy for breast cancer. https://cancer.ca/en/cancer-information/cancer-types/breast/treatment/targeted-therapy .
Mittmann N, Porter JM, Rangrej J et al (2014) Health system costs for stage-specific breast cancer: a population-based approach. Curr Oncol 21(6):281–293
doi: 10.3747/co.21.2143
pubmed: 25489255
pmcid: 4257111
Canadian Agency for Drugs and Technology in Health (2023) CADTH Reimbursement Review Trastuzumab Deruxtecan (Enhertu). Can J Health Technol 3 (1). https://www.cadth.ca/trastuzumab-deruxtecan-0 . Accessed 06 December 2023
Canadian Agency for Drugs and Technology in Health (2022) CADTH Reimbursement Review Tucatinib (Tukysa). Can J Health Technol 2 (1). https://www.cadth.ca/tucatinib . Accessed 06 December 2023
Virani SA, Dent S, Brezden-Masley C et al (2016) Canadian Cardiovascular Society Guideline for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 32(7):831–841
doi: 10.1016/j.cjca.2016.02.078
pubmed: 27343741
Hurry M, Hassan S, Seung SJ et al (2021) Real-world treatment patterns, survival, and costs for ovarian cancer in Canada: a retrospective cohort study using provincial administrative data. J Health Econ Outcomes Res 8(2):114–121
doi: 10.36469/jheor.2021.29145
pubmed: 34993257
pmcid: 8674196
Cancer Care Ontario. Guidelines for Staging Patients with Cancer (2005) https://ext.cancercare.on.ca/ext/databook/db1920/documents/Appendix/CCOCancerPatientStagingGuidelines.pdf
Wodchis W, Bushmeneva K, Nikitovic M, et al (2013) Guidelines on person- level costing using administrative databases in Ontario, Health System Performance Research Network. https://hspn.ca/wp-content/uploads/2019/09/Guidelines_on_PersonLevel_Costing_May_2013.pdf
Seung SJ, Hurry M, Hassan S et al (2019) Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol 26(2):102–107
doi: 10.3747/co.26.4555
pubmed: 31043811
pmcid: 6476449
Šidák Z (1967) Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 62(318):626–633
Perjeta Product Monograph. https://pdf.hres.ca/dpd_pm/00060125.PDF
Provincial Funding Summary—Pertuzumab (Perjeta-Herceptin Combo Pack) for Metastatic Breast Cancer. https://www.cadth.ca/sites/default/files/pcodr/pcodr_profund_pertuzumab_perjeta_mbc.pdf
Swain SM, Miles D, Kim SB et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519–530
doi: 10.1016/S1470-2045(19)30863-0
pubmed: 32171426
Diéras V, Miles D, Verma S et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732–742
doi: 10.1016/S1470-2045(17)30312-1
pubmed: 28526536
pmcid: 5531181
Ethier J-L, Desautels D, Robinson A et al (2021) Practice patterns and outcomes of novel targeted agents for the treatment of ERBB2-positive metastatic breast cancer. JAMA Oncol 7(9):e212140
doi: 10.1001/jamaoncol.2021.2140
pubmed: 34236387
pmcid: 8267844
Al Rabadi LS, Cook MM, Kaempf AJ et al (2021) Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with pertuzumab. BMC Cancer 21(1):1150
doi: 10.1186/s12885-021-08894-2
pubmed: 34706686
pmcid: 8549287
Moriwaki K, Uechi S, Fujiwara T et al (2021) Economic evaluation of first-line pertuzumab therapy in patients with HER2-positive metastatic breast cancer in Japan. Pharmacoecon Open 5(3):437–447
doi: 10.1007/s41669-020-00254-3
pubmed: 33483889
pmcid: 8333148
Currency Converter. https://www.bankofcanada.ca/rates/exchange/currency-converter .
Dai WF, Beca JM, Nagamuthu C et al (2022) Cost-effectiveness analysis of pertuzumab with trastuzumab in patients with metastatic breast cancer. JAMA Oncol 8(4):597–606
doi: 10.1001/jamaoncol.2021.8049
pubmed: 35201264
pmcid: 8874900
Brezden-Masley C, Fathers KE, Coombes M et al (2021) A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer. Breast Cancer Res Treat 185:507–515
doi: 10.1007/s10549-020-05960-4
pubmed: 33064230
Brezden-Masley C, Fathers KE, Coombes M et al (2020) A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer. Cancer Med. https://doi.org/10.1002/cam4.3038
doi: 10.1002/cam4.3038
pubmed: 32862501
pmcid: 7571809